Emergex Vaccines Holding Limited has announced promising results from a Phase I clinical trial conducted in Switzerland for their T cell-priming immune set-point candidate, known as CoronaTcP™. The purpose of the trial was to evaluate the safety and reactogenicity of CoronaTcP™ in healthy volunteers, and the findings indicate that it was generally well-tolerated by participants. Additionally, the study revealed the development of virus-specific effector and memory CD8+ T cells, which further supports Emergex's T cell-based approach to protect against RNA viruses such as SARS-CoV-1 and emerging variants of SARS-CoV-2.
The results of the trial demonstrated that CoronaTcP™ exhibited a favorable safety profile, with no serious adverse events related to treatment reported. Most adverse events were mild in nature, with injection-site pain being the most commonly reported side effect. Importantly, there were no significant differences in terms of safety or reactogenicity between participants who received high or low doses of CoronaTcP™.
Further analysis conducted on secondary immunogenicity showed that a majority